Ironwood Pharma (IRWD) AI Stock Analysis

• Market Cap: $582.12M
• Dividend Yield: N/A
• Average Volume (3M): 3.03M
• Price to Earnings (P/E): 29.6
• Beta (1Y): 0.55
• Revenue Growth: -10.42%
• EPS Growth: N/A
• Country: US
• Employees: 253
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.01
• Shares Outstanding: 163,058,320
• 10 Day Avg. Volume: 4,152,177
• 30 Day Avg. Volume: 3,030,556
• PEG Ratio: <0.01
• Price to Book (P/B): -9.96
• Price to Sales (P/S): 1.85
• P/FCF Ratio: 4.30
• Enterprise Value/Market Cap: 1.01
• Enterprise Value/Revenue: 1.99
• Enterprise Value/Gross Profit: 2.20
• Enterprise Value/Ebitda: 4.82
• 1Y Price Target: $7.50
• Price Target Upside: 110.08% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): 0.87
• Revenue Forecast (FY): $424.45M

• Rating: 55 Neutral
• Price Target: $4.00 ▲(12.04% Upside)
• Action: Reiterated Date: 02/27/26
• Date: Action: Reiterated 02/27/26

The score is driven primarily by mixed fundamentals: strong cash flow and improved 2025 profitability are weighed down by negative equity and weakening revenue. Technicals add pressure due to a weak near-term trend, while the earnings call supports the outlook with upbeat 2026 guidance and a deleveraging path; valuation is middling with no dividend support.

Positive Factors

Free cash flow & profitability rebound

Ironwood generated materially improved operating cash and adjusted EBITDA in 2025, producing strong free cash flow that supports the company’s stated deleveraging plan, funds near‑term obligations and R&D, and reduces execution risk for strategic programs over the next 2–6 months.

LINZESS durable commercial franchise

LINZESS remains a high‑share, high‑volume GI franchise with sustained prescription growth and scale that drives recurring profit‑share revenues. The large patient base and new-to-brand growth provide a durable revenue and cashflow foundation to support operations and pipeline investment.

Regulatory and pipeline progress (aproglutide/STARS II)

Management secured FDA alignment on a confirmatory STARS II design and plans site activation, which clarifies the regulatory path for aproglutide. This reduces binary regulatory uncertainty and preserves the potential for a materially value‑creating new GI therapy upon successful execution.

Negative Factors

Negative equity and weak capital structure

A negative equity position signals accumulated deficits and constrains financial flexibility, increasing vulnerability to revenue shocks. Although debt has declined, the impaired capital structure limits ability to absorb setbacks or pursue opportunistic investments without sustaining strong cash generation.

Declining revenue and net price erosion

Top‑line weakness driven by net price erosion (Medicare Part D impacts and rebate timing) compresses the revenue base that funds profit‑sharing and R&D. Sustained price pressure and a worsening payer mix could reduce long‑term cash flow and margin durability absent offsetting volume or price recovery.

Clinical/regulatory execution risk for aproglutide

The FDA‑required confirmatory trial increases cost and timing to approval; enrolling a 124‑patient rare‑disease trial carries execution and timeline risk. Delays or negative outcomes could materially defer projected aproglutide revenues and the company’s deleveraging plan.

Ironwood Pharma Business Overview & Revenue Model

Company Description

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

How the Company Makes Money

Ironwood Pharmaceuticals generates revenue primarily through the sales of its flagship product, Linzess, which is marketed in collaboration with AbbVie. The company earns royalties from its partner on sales of Linzess, in addition to receiving milestone payments tied to sales performance. Other revenue streams may include licensing agreements and collaborations that provide upfront payments and development milestones. The company's focus on expanding its product pipeline and potential new indications for existing therapies also contributes to its earnings potential.

Ironwood Pharma Financial Statement Overview

Summary

Strong 2025 profitability rebound and solid free cash flow generation support the score, but it is materially offset by declining revenue and a pressured capital structure with negative equity despite improving debt levels.

Income Statement

Profitability rebounded strongly in 2025 with net margin near ~39% versus near breakeven in 2024, while gross margins remain exceptionally high across periods. However, the revenue trajectory is weakening (down ~13% in 2025 after modest declines in 2024), and results have shown material volatility historically (including a very large loss in 2023). Overall: strong margins and improved earnings power, but inconsistent growth and choppy bottom-line history.

Balance Sheet

The balance sheet is pressured by negative equity in the most recent two years (2024–2025), which signals accumulated deficits and reduces financial flexibility. While total debt has come down meaningfully from 2023 to 2025, leverage remains a key risk given the negative equity position and comparatively small asset base. Overall: improving debt level, but weak capital structure and elevated balance-sheet risk.

Cash Flow

Cash generation is a clear strength: operating cash flow and free cash flow are both solid and closely track reported earnings, with a sharp free-cash-flow rebound in 2025. That said, cash flow has been uneven year to year (notably lower in 2024 vs. 2023), and the company’s ability to cover obligations depends on sustaining these cash flows. Overall: strong free cash flow profile with some volatility.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	296.15M	351.41M	442.74M	410.60M	413.75M
Gross Profit	294.27M	343.86M	436.59M	409.18M	343.35M
EBITDA	104.65M	97.73M	197.41M	261.44M	233.74M
Net Income	24.02M	880.00K	-1.00B	175.06M	528.45M
Balance Sheet
Total Assets	396.90M	350.91M	471.07M	1.10B	1.13B
Cash, Cash Equivalents and Short-Term Investments	215.46M	88.56M	92.15M	656.20M	620.13M
Total Debt	212.80M	599.48M	715.54M	415.92M	475.80M
Total Liabilities	451.77M	652.24M	817.37M	448.14M	521.02M
Stockholders Equity	-54.87M	-301.33M	-346.30M	652.38M	605.91M
Cash Flow
Free Cash Flow	127.01M	103.41M	183.15M	273.63M	261.63M
Operating Cash Flow	127.04M	103.55M	183.43M	273.76M	261.89M
Investing Cash Flow	-34.00K	-142.00K	-1.03B	-136.00K	-265.00K
Financing Cash Flow	216.00K	-106.97M	277.16M	-237.55M	-4.55M

Ironwood Pharma Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 3.57
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IRWD, the sentiment is Neutral. The current price of 3.57 is below the 20-day moving average (MA) of 4.29, below the 50-day MA of 4.24, and above the 200-day MA of 2.16, indicating a neutral trend. The MACD of -0.25 indicates Positive momentum. The RSI at 38.55 is Neutral, neither overbought nor oversold. The STOCH value of 31.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IRWD.

Ironwood Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PCRX	67 Neutral	$861.62M	135.46	0.96%	―	3.14%	―
ANIP	67 Neutral	$1.69B	22.44	15.11%	―	48.87%	―
COLL	62 Neutral	$1.32B	24.23	23.70%	―	26.34%	-32.79%
IRWD	55 Neutral	$582.12M	29.63	―	―	-10.42%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
EVO	46 Neutral	$1.18B	-6.60	-17.46%	―	-1.19%	5.06%

Ironwood Pharma Corporate Events

Ironwood Pharma Resolves Ferring Dispute, Amends License Terms

On December 18, 2025, Ironwood Pharmaceuticals’ subsidiary VectivBio AG amended its exclusive license agreement with Ferring International Center to revise financial and intellectual property terms, including a total payment obligation of $12.5 million—an initial $7.5 million followed by $5 million due by December 31, 2026, subject to possible acceleration—alongside new tiered royalty commitments on net sales of licensed products. Under the revised structure, VectivBio will pay Ferring a high single-digit royalty for seven years following first commercial sale of each licensed product and a reduced low single-digit royalty thereafter until relevant patent coverage expires, while the amendment also clarifies ownership and other IP rights; on the same date, VectivBio, Ironwood and Ferring entered into a settlement and release resolving all claims related to Ferring’s lawsuit in the U.S. District Court for the Eastern District of Texas, removing a legal overhang and providing clearer economic and IP terms around the licensed portfolio.

The most recent analyst rating on (IRWD) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Ironwood Pharma stock, see the IRWD Stock Forecast page.